本页面由Tiger Trade Technology Pte. Ltd.提供服务

再鼎医药

25.08
+1.024.24%
盘后:25.080.00000.00%19:30 EDT
成交量:80.55万
成交额:2,013.85万
市值:28.18亿
市盈率:-14.73
高:25.33
开:24.20
低:24.10
收:24.06
52周最高:29.77
52周最低:15.96
股本:1.12亿
流通股本:9,711.04万
量比:1.09
换手率:0.83%
股息:- -
股息率:- -
每股收益(TTM):-1.7030
每股收益(LYR):-1.6026
净资产收益率:-26.91%
总资产收益率:-14.75%
市净率:4.64
市盈率(LYR):-15.65

数据加载中...

2026/08/20

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/08/19

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/08/12

关联方拟减持公告

Form 144 | Zai Lab Ltd董事 William Lis 计划减持8506股,总价约$212650
2026/08/11

关联方拟减持公告

Form 144 | Zai Lab Ltd 高管 Chen Yajing 拟减持619股,市值约15475美元
2026/08/06

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2026/08/06

重要事件披露

Form 8-K - Current report
2026/06/30

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/06/26

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/06/26

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/06/26

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/06/22

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/06/18

重要事件披露

Form 8-K - Current report
2026/06/11

超过5%披露

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
2026/05/21

重要事件披露

Form 8-K - Current report
2026/05/18

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/05/15

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/05/14

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/05/14

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/05/13

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2026/05/07

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]